Poor ICI treatment response has been linked to the tumors ability to disguise antigen presentation and generate an immunosuppressive microenvironment. In addition, most conventional immunotherapies are not designed to educate the patients immune system on how to recognize a variety of tumor antigens and neoantigens.
Amid this landscape, a clinical-stage biopharmaceutical company has developed a new multimodal biological approach that leverages the ability of viral gene constructs to activate cancer-killing mechanisms, exposing multiple tumor antigens to the immune system, resulting in vaccination against the tumor while inhibiting the immunosuppressive tumor microenvironment.
Candel Therapeutics, Inc. (NASDAQ: CADL) is developing a product candidate that is being studied in lung, pancreatic and prostate cancers. Candels most advanced viral immunotherapy candidate, CAN-2409, is an investigational off-the-shelf replication-defective adenovirus designed to induce an individualized, systemic immune response against the patients own tumor.
Part of the companys adenovirus platform, CAN-2409 is injected directly into the tumor or target tissue using a localized injection, akin to the standard approach for vaccination.
CAN-2409's adenoviral construct serves as a vector to transport the HSV-thymidine kinase gene into tumor cells at the site of injection. These tumor cells can then express HSV-thymidine kinase, which converts generic, FDA-approved anti-herpes drugs such as ganciclovir, acyclovir and valacyclovir into a toxic nucleotide analog that blocks DNA synthesis in dividing cells.
Cancer cells exposed to the toxic nucleotide analog in the tumor microenvironment have been observed to undergo immunogenic cell death. Simultaneously, the adenoviral serotype 5 capsid protein elicits a strong pro-inflammatory signal in the tumor microenvironment, creating the optimal conditions to induce a specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad and systemic anti-tumor activity.
CAN-2409 is currently being studied in an open-label, phase 2 clinical trial in non-small cell lung cancer (NSCLC) and in randomized, controlled, blinded phase 2b and phase 3 clinical trials in prostate cancer. The company has recently released very encouraging data for CAN-2409s ability to improve overall survival in non-metastatic pancreatic cancer, with topline overall survival data in non-small cell lung cancer planned for this quarter (Q2 2024) and results from the prostate clinical trials later this year (Q4 2024).
When it comes to NSCLC, the company previously presented data from the phase 2 clinical trial in which patients received two administrations of CAN-2409 plus prodrug. Those patients demonstrated the following:
1) Increased infiltration of CD8+ cytotoxic T cells in the tumor microenvironment, systemic expansion of effector T cells and increased soluble granzyme B levels in peripheral blood;
2) Favorable changes in the trajectory of tumor progression;
3) Decreased tumor size of target lesions in most patients; and
4) Reduced size of uninjected tumor lesions.
The CAN-2409 immunotherapy antitumor strategy aims to increase the number of long survivors beyond 10 to 13 months.
As previous work has shown that progressive disease could be converted into stable disease in most patients with non-small cell lung cancer after CAN-2409 treatment, the hypothesis is that this will translate into improved survival.
When it comes to pancreatic cancer, the company reported notable improvements in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC) after experimental treatment with CAN-2409. The estimated overall survival rate was 71.4% at 24 months in CAN-2409-treated patients versus only 16.7% in the control arm after chemoradiation.
In 2023, CAN-2409 received Fast Track Designation for both non-small cell lung cancer and pancreatic cancer, a validation from the FDA on its potential. CAN-2409 plus valacyclovir in combination with continued PD-1/PD-L1 agents is being evaluated in an ongoing, open-label phase 2 clinical trial in patients with late-stage NSCLC and an inadequate response to anti-PD(L)-1 therapy. In 2024, CAN-2409 also received Orphan Drug Designation from the FDA for CAN-2409 in borderline resectable pancreatic cancer.
In the upcoming year, Candel plans to announce data readouts for the following:
1) Phase 2 topline overall survival (OS) data for CAN-2409 in NSCLC, expected in Q2 2024;
2) Phase 2 topline data for CAN-2409 in low-to-intermediate-risk, localized, non-metastatic prostate cancer, expected in Q4 2024;
3) Phase 3 topline data for CAN-2409 in localized intermediate/high-risk prostate cancer, expected in Q4 2024.
Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). Finally, Candels enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
This article includes certain disclosures that contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including the timing and availability of additional data, key data readout milestones, including CAN-3110 in HGG; expectations regarding the potential benefits conferred by Fast Track Designation; expectations regarding the therapeutic benefit of its programs, including the potential for its programs to extend patient survival; and expectations regarding cash runway and expenditures. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on managements current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Companys programs; that final data from our pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Companys ability to efficiently discover and develop product candidates; the Companys ability to obtain and maintain regulatory approval of product candidates; the Companys ability to maintain its intellectual property; the implementation of the Companys business model, and strategic plans for the Companys business and product candidates, and other risks identified in the Companys SEC filings, including the Companys most recent Quarterly Report on Form 10-Q filed with the SEC, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Companys views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Dubai, UAE, June 18, 2026-GivTrade today reaffirmed its commitment to transparency, regulatory compliance, and client protection as it marks seven years of growth and service to traders across international markets.
Founded in 2019, GivTrade has grown into an international financial services group serving more than 100,000 traders worldwide through its regulated operations and partner network. GivTrade forms part of Fawaz Investment Holding, a Qatar-based investment group supporting the continued growth and development of its international operations.
Givtrade At A Glance
• Established in 2019
• More than 100,000 traders served globally
• UAE CMA Category 5 licensed entity
• FSC Mauritius regulated trading operations
• Headquarters in Qatar through Fawaz Investment Holding (QFC)
• Strategic partnerships with TradingView and LaLiga
• Best Market Execution Technology Award recipient (Jeddah Fintech Week 2025)
• Expanding operations across key international markets
Regulatory Status
GivTrade operates through licensed entities in multiple jurisdictions.
United Arab Emirates
GivTrade Financial Services L.L.C S.O.C holds UAE CMA Category 5 Licence No. 20200000367 issued by the UAE Securities and Commodities Authority (SCA).
Mauritius
Trading services are provided through GivTrade’s regulated entity licensed by the Financial Services Commission (FSC) of Mauritius under Licence No. GB22201329 – Investment Dealer (Full Service Dealer, Excluding Underwriting).
Both licences are active and publicly verifiable through their respective regulators.
Corporate Structure
GivTrade is part of Fawaz Investment Holding, a Qatar-based holding company established within the Qatar Financial Centre (QFC). Fawaz Investment Holding serves as the Group’s holding and operational headquarters, overseeing the strategic development and growth of its affiliated businesses and investments. The holding company does not provide regulated trading services or investment dealing activities to retail clients.
Client-facing regulated activities are conducted exclusively through the Group’s appropriately licensed entities in their respective jurisdictions.
Global Partnerships And Market Presence
GivTrade has established strategic partnerships and marketing collaborations with internationally recognised organisations and platforms, including LaLiga and TradingView.
Industry Recognition
At Jeddah Fintech Week 2025, held in November 2025, GivTrade was honoured with the BestMarket Execution Technology Award, recognising the company’s investment in trading
infrastructure, execution quality, and technology-driven solutions for traders.
Guidance For Traders
GivTrade encourages all traders to verify licences directly through regulator websites, review legal disclosures carefully, and rely on official regulatory records when evaluating financial service providers.
Future Growth And Expansion
Looking ahead, GivTrade continues to invest in its global regulatory framework. In addition to its existing licences and operations, the Group is evaluating further regulatory opportunities, including a future licence application with the Cyprus Securities and Exchange Commission (CySEC), subject to all regulatory approvals and applicable legal requirements.
Statement From The CEO
“The UAE remains one of the most important markets in our long-term growth strategy. As we continue to expand our presence in the region, we are investing in a new larger office in Dubai, growing our team, and strengthening the infrastructure required to support our future ambitions. Together with our regulated international operations, these investments reflect our confidence in the future of GivTrade and our commitment to serving traders with transparency, professionalism, and trust.”
— Hassan Fawaz, Chief Executive Officer
About Givtrade
Founded in 2019, GivTrade is an international financial services group serving more than 100,000 traders worldwide through its regulated operations and partner network. The Group maintains its headquarters in Qatar through Fawaz Investment Holding within the Qatar Financial Centre (QFC) and operates regulated entities in multiple jurisdictions.
This statement is issued for informational purposes only and does not constitute investment advice, an offer, or a solicitation to provide financial services in any jurisdiction where such activity would be restricted or prohibited.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
New UV-Resistant, Zero-Maintenance Plants Deliver Year-Round Greenery for Homes, Offices, and Outdoor Spaces
CHARLOTTE, NC, United States, 18th Jun 2026 – Vitalismo, a brand specializing in high-quality lifelike artificial plants, has officially expanded its Amazon product lineup with two new decorative tree collections: artificial cedar topiary and artificial olive tree. Designed for both residential and commercial environments, the new additions reflect the growing demand for low-maintenance greenery solutions that combine aesthetics, convenience, and long-term durability.
As consumer interest in nature-inspired interiors continues to rise, artificial plants are becoming an increasingly popular choice for homes, offices, hospitality venues, and retail spaces. Unlike live plants, artificial greenery requires no watering, pruning, fertilizing, or specialized lighting conditions, while maintaining a consistent appearance throughout the year. Advances in simulation craftsmanship and weather-resistant materials have further accelerated adoption of large decorative artificial trees, including olive and cedar varieties, across a wide range of indoor and outdoor settings.
“More consumers today are seeking home décor solutions that balance beauty with convenience,” said a spokesperson for Vitalismo. “Through realistic, low-maintenance artificial plants, we aim to help people create welcoming green spaces that remain vibrant year-round while reducing the effort typically associated with plant care.”
Vitalismo was founded with a simple mission: to help consumers create vibrant, evergreen spaces without the time and resources traditionally required for plant care.
Artificial Cedar and Olive Tree Collections Built Around Evergreen Beauty
Vitalismo’s latest Amazon launches address this trend directly, offering two distinct tree styles that combine detailed craftsmanship with long-term durability and no upkeep requirements.
The Vitalismo Artificial Topiary Cedar Trees are available in five size options, ranging from 2 feet to 6 feet tall. The artificial topiary cedar tree is constructed from high-quality PE material and plastic, with branches and leaves engineered using simulation technology to reproduce the natural layered growth pattern of a cedar tree. The leaves feature clearly defined textures, along with newly designed buds that enhance the sense of organic growth.
A key functional feature is the flexibility of the branches: each unit allows users to bend and reshape the foliage to suit the dimensions and layout of the intended space. This makes the cedar topiary adaptable to narrow entryways, covered patios, balconies, and front porch placements equally well. The trees are odorless, weather-tolerant, and carry a UV-resistant treatment that prevents color fading from prolonged sun exposure, making them suitable for semi-exposed outdoor use as well as indoor display.
Most recently, Vitalismo introduced the Artificial Indoor Olive Trees, which are available in four size options, spanning 5 feet to 8 feet in height. Depending on the size selected, individual units feature between 641 and 1530 meticulously crafted leaves with clear textures, and include decorative artificial olive fruits.
Each unit ships pre-assembled in a heavy-duty pot constructed from durable plastic and concrete for superior stability, and includes a white round planter. The collection has received multiple industry recognitions, including the MUSE Design Awards, American Good Design Award, and Gold Award distinctions, highlighting its realistic appearance, craftsmanship, and decorative versatility.
Looking Ahead
Looking ahead, Vitalismo remains committed to innovation and sustainability, focusing on creating realistic, high-quality artificial plants that bring vibrant greenery to homes, offices, and commercial spaces year-round. The brand plans to continue developing increasingly lifelike and premium products to provide consumers with the experience of a flourishing natural environment without the challenges of traditional plant care.
At the same time, Vitalismo aims to explore more environmentally friendly and durable materials to extend product longevity and reduce resource waste associated with frequent replacements. The company also intends to expand its artificial plant collections to cater to a wider range of decorative needs across different spaces.
Both the Vitalismo Artificial Topiary Cedar Trees and the Artificial Indoor Olive Trees are currently available on Amazon, with multiple size options listed on each product page.
Vitalismo is a brand specializing in high-quality, lifelike artificial plants, dedicated to providing maintenance-free, evergreen decorative solutions for homes and offices. All Vitalismo products feature UV-resistant and fade-resistant finishes, offering a realistic appearance across every product line. The brand’s plants are non-toxic and safe for households with pets and children, making them a practical choice for a wide range of customers.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
CJ William, a Surfside, Florida luxury watch and Hermes dealer, today released its 2026 Luxury Watch Resale Report. The annual analysis combines public secondary-market indices with dealer transaction activity, finding that Patek Philippe led major brands in 2025 and that select Cartier references quietly outperformed the broader market.
SURFSIDE, Fla. – CJ William, a South Florida luxury watch and Hermes dealer, today released its 2026 Luxury Watch Resale Report, an annual analysis of which timepieces held, gained, or lost value across the secondary market over the past year.
The headline finding: luxury watch resale value turned a corner in 2025. After roughly two years of decline, prices stabilized and the strongest references posted real gains. Patek Philippe led all major brands at about 7.7 percent for the year, driven by the Aquanaut and Nautilus, while Rolex stabilized and Audemars Piguet returned to growth. The report also flags a less obvious trend: select Cartier references outperformed the broader market even as headline hype models cooled.
“Everyone watches the Daytona and the Nautilus, and they should, because top-tier Patek, Rolex, Audemars Piguet and Richard Mille continue to hold and in many cases grow their value,” said Eitan Cohen, founder of CJ William. “But the buyers walking into our Surfside showroom in 2026 are asking smarter questions about value, and brands like Cartier are rewarding them.”
“The white-dial Daytona Panda is the single most-requested watch on our desk right now,” Cohen added. “Steel sports Rolex, the Nautilus and the Aquanaut move fast in South Florida, and Cartier prices have quietly climbed even as demand held steady.”
Key findings from the 2026 report include the top 10 references by value retention over the past year, the brands that recovered fastest after the market correction, where value is hiding in 2026, and a South Florida market cut showing which models move fastest in Miami, Surfside and Bal Harbour.
CJ William compiled the report from leading public secondary-market indices combined with its own buying and selling activity, giving a dealer-side view of real demand rather than listing prices alone.
CJ William buys and sells Rolex, Patek Philippe, Audemars Piguet, Richard Mille, Cartier and other luxury watches, with in-house New York authentication, an 18-month warranty and fully insured FedEx overnight shipping. The firm makes same-day offers and welcomes in-person appointments at its Surfside showroom.
About CJ William
CJ William is a luxury watch, Hermes and antique silver dealer at 9573 Harding Avenue, Surfside, FL 33154. The showroom buys, sells and sources luxury timepieces and offers corporate gifting nationwide. Invoicing entity: David and Sons Watches LLC.
Media Contact CJ William Email: e@cjwilliam.com Phone: (347) 510-0668 Website: cjwilliam.com
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
